Established Investigator Award in Cancer Prevention & Control.

The objective of the NCI Established Investigator Award in Cancer Prevention and Control (K05) is to provide qualified researchers with protected time to devote to research and mentoring. The award is designed for established scientists who have already demonstrated a sustained, high level of research and mentoring productivity and who need K05 support to continue these activities. The award provides partial salary support for up to 5 years and for up to 50 percent effort. It is renewable for one additional 5-year period. Examples of cancer prevention and control research and mentoring activities supported by this funding opportunity include, bur are not limited to, the following areas: 1) the identification of modifiable risk factors for cancer, such as nutrient intake, exercise, exposure to carcinogens, or behavioral lifestyle factors; 2) molecular epidemiology, to identify allelic variants in genes in relation to cancer incidence or course; 3) studies of interactions of genetic and endogenous factors (e.g., hormonal milieu) with exogenous risk factors as related to cancer incidence and course; 4) the identification of community structural and social variables (e.g., location of health care facilities, access to health care, culturally conditioned attitudes affecting health behaviors) that are barriers to or facilitators of cancer prevention and control efforts; 5) studies of the above factors in relation to health disparities in cancer incidence and outcomes; 6) identification of biomarkers and clinical/screening studies of their utility as predictors of cancer risk and outcome; 7) behavioral research to identify cognitive or motivational attributes that affect the individual's acceptance of screening guidelines or treatments and propensity to engage in health-promoting or cancer risk-reducing behaviors; 8) the development of preventive interventions to decrease cancer risk behaviors and/or increase health-promoting behaviors; 9) chemoprevention from studies of the identification and early-phase characterization of candidate agents to preventive intervention trials; 10) studies of nutritional supplements or complementary/alternative interventions in relation to cancer prevention and control; 11) health services research, including patient outcome studies, practice research, and medical decision analyses related to cancer prevention or to cancer care and patient outcomes; 12) palliative care studies, including interventions to improve quality of life; 13) survivorship research, including studies of outcomes and quality of life as related to cancer course, treatments, and treatment side effects; and 14) studies of the effectiveness of cancer health communications in reducing high risk behaviors or in increasing participation in screening activities.

This funding opportunity will use the K05 award mechanism. The Established Investigator Award in Cancer Prevention & Control is a special NCI modification of the NIH Senior Scientist Award or K05 grant mechanism. In addition, the institution must demonstrate a commitment to the candidate and the candidate's goals for research, career development, and mentoring.

This funding opportunity uses the just-in-time budget concepts. It also uses the nonmodular budget format described in the PHS 398 application instructions (see http://grants.nih.gov/grants/funding/ phs398/phs398.html). The applicant should follow the PHS 398 instructions for budget information, providing only the total direct costs requested for each year and for the entire proposed period of support, and provide budget justification information. For further assistance contact GrantsInfo, 301-435-0714, (telecommunications for the hearing impaired: TTY 301-451-0088) or by e-mail: [e-mail].

Applications must be prepared using the most current PHS 398 research grant application instructions and forms. Applications must have a Dun & Bradstreet (D&B) Data Universal Numbering System number as the universal identifier when applying for Federal grants or cooperative agreements. The D&B number can be obtained by calling 866-705-5711 or through the web site at http://www.dnb.com/us/. The D&B number should be entered on line 11 of the face page of the PHS 398 form.

The deadline for receipt of applications is July 2, 2008. The full PA is available at http://grants.nih. gov/grants/guide/pa-files/PAR-05-145.html

Contact: Mary C. Blehar, Cancer Training Branch, National Cancer Institute, 6116 Executive Boulevard, Suite 7019, MSC 8346, Bethesda, MD 20892-8346 USA, 301-496-8580, fax: [phone], e-mail: [e-mail]. Reference PAR-03-149